US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
INmune Bio Inc (INMB)
INmune Bio Inc (INMB) ニュース

INMB

INmune Bio (INMB)

INmune Bio Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:INMB

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/10	05 : 05	GlobeNewswire Inc.	INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update	NASDAQ:INMB	INmune Bio Inc
2024/05/07	21 : 00	GlobeNewswire Inc.	INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9	NASDAQ:INMB	INmune Bio Inc
2024/04/30	21 : 00	GlobeNewswire Inc.	INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years	NASDAQ:INMB	INmune Bio Inc
2024/04/29	21 : 00	GlobeNewswire Inc.	INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	NASDAQ:INMB	INmune Bio Inc
2024/04/25	22 : 00	GlobeNewswire Inc.	INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:INMB	INmune Bio Inc
2024/04/23	21 : 00	GlobeNewswire Inc.	INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	NASDAQ:INMB	INmune Bio Inc
2024/04/22	21 : 00	GlobeNewswire Inc.	INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering	NASDAQ:INMB	INmune Bio Inc
2024/04/08	21 : 00	GlobeNewswire Inc.	INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	NASDAQ:INMB	INmune Bio Inc
2024/03/29	05 : 01	GlobeNewswire Inc.	INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update	NASDAQ:INMB	INmune Bio Inc
2024/03/27	05 : 01	GlobeNewswire Inc.	INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28	NASDAQ:INMB	INmune Bio Inc
2024/03/13	21 : 00	GlobeNewswire Inc.	INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy	NASDAQ:INMB	INmune Bio Inc
2024/03/05	22 : 00	GlobeNewswire Inc.	INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™	NASDAQ:INMB	INmune Bio Inc
2024/02/12	23 : 00	GlobeNewswire Inc.	INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:INMB	INmune Bio Inc
2024/02/06	23 : 00	GlobeNewswire Inc.	INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024	NASDAQ:INMB	INmune Bio Inc
2024/01/30	22 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INMB	INmune Bio Inc
2024/01/30	22 : 00	GlobeNewswire Inc.	INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program	NASDAQ:INMB	INmune Bio Inc
2024/01/16	22 : 30	GlobeNewswire Inc.	ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology	NASDAQ:INMB	INmune Bio Inc
2024/01/03	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INMB	INmune Bio Inc
2024/01/02	22 : 00	GlobeNewswire Inc.	INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer	NASDAQ:INMB	INmune Bio Inc
2023/12/19	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INMB	INmune Bio Inc
2023/12/19	06 : 05	Edgar (US Regulatory)	Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]	NASDAQ:INMB	INmune Bio Inc
2023/12/19	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INMB	INmune Bio Inc
2023/12/19	06 : 01	GlobeNewswire Inc.	INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA	NASDAQ:INMB	INmune Bio Inc
2023/11/30	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INMB	INmune Bio Inc
2023/11/29	22 : 00	GlobeNewswire Inc.	INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium	NASDAQ:INMB	INmune Bio Inc
2023/11/28	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INMB	INmune Bio Inc
2023/11/27	22 : 00	GlobeNewswire Inc.	INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease	NASDAQ:INMB	INmune Bio Inc
2023/11/16	06 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INMB	INmune Bio Inc
2023/11/15	23 : 00	GlobeNewswire Inc.	INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe	NASDAQ:INMB	INmune Bio Inc
2023/11/14	01 : 31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INMB	INmune Bio Inc

Showing the most relevant articles for your search:NASDAQ:INMB

1 2 3 4 5 6 7 8 9 10 次へ >>

BNP Paribas (QX)

Invesco QQQ Trust Series 1

US Dollar vs Yen

Verizon Communications

Financial Select Sector

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約